- 29 Jul 2017 Allan Bradley at Canaccord Genuity Growth Conference
- 9 Jan 2017 Kymab expands Infectious Disease Programmes
- 24 Nov 2016 Kymab secures US$100 million Series C funding
- 6 May 2015 Kymab secures US$90 million funding
- 16 May 2014 Gates and Wellcome Trust invest in Kymab
- 12 Jul 2010 Wellcome Trust £20 million financing agreement
We use cookies on our website. Carry on browsing if you’re happy with this or find out more
Featured article: Novel COVID-19 Antibody Therapy Candidates Identified by Leading UK Biotech Consortium
Potent antibody drug combinations identified
Read article
Featured article: Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis
Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases a...
Read article
Featured article: Kymab wins Supreme Court case against Regeneron
Landmark UK Supreme Court decision invalidates Regeneron Patent claims
Read article